Phenethyl isothiocyanate enhances adriamycin‑induced apoptosis in osteosarcoma cells

Fan,Qie; Zhan,Xinli; Xiao,Zengming; Liu,Chong

doi:10.3892/mmr.2015.4187

Phenethyl isothiocyanate enhances adriamycin‑induced apoptosis in osteosarcoma cells

Authors:
- Qie Fan
- Xinli Zhan
- Zengming Xiao
- Chong Liu
View Affiliations

Affiliations: Department of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: August 5, 2015 https://doi.org/10.3892/mmr.2015.4187
Pages: 5945-5950

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adriamycin (ADM) is a first‑line agent administered during the therapeutic regimes against osteosarcoma. Clinical administration of ADM produces systemic toxicity and resistance in patients, which restricts its applicability. In the present study the effects of phenethyl isothiocyanate (PEITC) on ADM‑induced apoptosis in osteosarcoma cells was evaluated. Using U2‑OS osteosarcoma cell line cells, treatment with PEITC or ADM for 24 h was observed to dose‑dependently inhibit proliferation of U2‑OS cells with half maximal inhibitory concentration (IC50) values of 5.33 µM and 10.32 µg/ml, respectively. When U2‑OS cells were treated with a combination of the two agents, the inhibition was apparently enhanced, as the IC50 values decreased to 2 µM for PEITC and 1 µg/ml for ADM. Flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling revealed that treatment with PEITC or ADM alone reduced the viability of the U2‑OS cells. Furthermore, the viability of the U2‑OS cells was additionally reduced when treatment was with PEITC and ADM together. Supporting this finding, the activity and expression of caspase‑3 were observed to be enhanced in the U2‑OS cells following treatment with either PEITC or ADM, or a combination of the two. These results clearly indicate that PEITC enhances ADM‑induced apoptosis in osteosarcoma cells.

View Figures

View References

1	Dotan A, Dadia S, Bickels J, Nirkin A, Flusser G, Issakov J, Neumann Y, Cohen I, Ben-Arush M, Kollender Y, et al: Expandable endoprosthesis for limb-sparing surgery in children: Long-term results. J Child Orthop. 4:391–400. 2010. View Article : Google Scholar :
2	Broadhead ML, Clark JC, Myers DE, Dass CR and Choong PF: The molecular pathogenesis of osteosarcoma: A review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
3	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
4	Ottaviani G and Jaffe N: The etiology of osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar
5	Weiss RB: The anthracylcines: Will we ever find a better doxorubicin? Semin Oncol. 19:670–686. 1992.PubMed/NCBI
6	Thorna CF, Oshiroa C, Marshe S, Hernandez-Boussard T, McLeod H, Kleina TE and Altman RB: Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics. 21:440–446. 2011. View Article : Google Scholar
7	Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W and Chiao JW: Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res. 26:1225–1230. 2006.PubMed/NCBI
8	Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D and Chiao JW: Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol. 28:1287–1293. 2006.PubMed/NCBI
9	Lu Q, Lin X, Feng J, Zhao X, Gallagher R, Lee MY, Chiao JW and Liu D: Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol. 9:1–6. 2008.
10	Stan SD, Singh SV, Whitcomb DC and Brand RE: Phenethyl isothiocyanate inhibits proliferation and induces apoptosis in pancreatic cancer cells in vitro and in a MIAPaca2 xenograft animal model. Nutr Cancer. 66:747–755. 2014.Nov 6 2013 [Epub ahead of print]. View Article : Google Scholar :
11	Huang SH, Hsu MH, Hsu SC, Yang JS, Huang WW, Huang AC, Hsiao YP, Yu CC and Chung JG: Phenethyl isothiocyanate triggers apoptosis in human malignant melanoma A375.S2 cells through reactive oxygen species and the mitochondria-dependent pathways. Hum Exp Toxicol. 33:270–283. 2014. View Article : Google Scholar
12	Sarkars R, Mukherjee S and Roy M: Targeting heat shock proteins by phenethyl isothiocyanate results in cell-cycle arrest and apoptosis of human breast cancer cells. Nutr Cancer. 65:480–493. 2013. View Article : Google Scholar : PubMed/NCBI
13	Xiao D and Singh SV: p66Shc is indispensable for phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. Cancer Res. 70:3150–3158. 2010. View Article : Google Scholar : PubMed/NCBI
14	Cang S, Ma Y, Chiao JW and Liu D: Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells. Exp Hematol Oncol. 3:52014. View Article : Google Scholar : PubMed/NCBI
15	Lee DH, Kim DW, Lee HC, Lee JH and Lee TH: Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun. 446:815–521. 2014. View Article : Google Scholar : PubMed/NCBI
16	Tang T, Song X, Liu YF and Wang WY: PEITC reverse multi-drug resistance of human gastric cancer SGC7901/DDP cell line. Cell Biol Int. 38:502–510. 2014. View Article : Google Scholar
17	Liu K, Cang S, Ma Y and Chiao JW: Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell Int. 13:102013. View Article : Google Scholar : PubMed/NCBI
18	Xiao D and Singh SV: Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo. Pharm Res. 27:722–731. 2010. View Article : Google Scholar : PubMed/NCBI
19	Gupta P and Srivastava SK: Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med. 10:802012. View Article : Google Scholar : PubMed/NCBI
20	Yuang P, Chen BA, Cheng J, Ma XD, Liu DL and Lu QY: Effect of phenylhexyl isothiocyanate on adriamycin resistance of K562/A02 cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 17:352–357. 2009.In Chinese. PubMed/NCBI
21	Mukherjee S, Bhattacharya RK and Roy M: Targeting protein kinase C (PKC) and telomerase by phenethyl isothiocyanate (PEITC) sensitizes PC-3 cells towards chemotherapeutic drug-induced apoptosis. J Environ Pathol Toxicol Oncol. 28:269–282. 2009. View Article : Google Scholar
22	Massart C, Barbet R, Genetet N and Gibassier J: Doxorubicin induces Fas-mediated apoptosis in human thyroid carcinoma cells. Thyroid. 14:263–270. 2004. View Article : Google Scholar : PubMed/NCBI
23	Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D'Arcy P, Zhivotovsky B, Childs R and Lundqvist A: Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer. 133:1643–1652. 2013. View Article : Google Scholar : PubMed/NCBI
24	Degterev A, Boyce M and Yuan J: A decade of caspases. Oncogene. 22:8543–8567. 2003. View Article : Google Scholar : PubMed/NCBI